Business Wire

Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices

Share

Quectel Wireless Solutions, a global IoT solutions provider, today announces Quectel Certification Services, its range of IoT device certification and testing services that will enable customers to rapidly certify their IoT devices with regulatory organisations such as the FCC, IC, CE, ANATEL, RCM, KC, Jate and Telec and carrier organisations including AT&T, Verizon, T-Mobile, Rogers, TELUS and Vodafone. This service will enable customers’ devices to gain certifications in under eight weeks and is not only the fastest time to market for IoT device manufacturers, but also the industry’s most cost-effective offering.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230314005140/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

Quectel Certification Services offering speeds up time to market and takes away certification cost and complexities for IoT devices (Photo: Business Wire)

Certification across these disciplines is complex to achieve, involves multiple layers of certification from disparate organisations and, typically, local and regional authorities award certifications for device deployments in their own territories. The Quectel Certification Services span regulatory, conformance and carrier compliance requirements plus certifications for industry-specific devices and environmental and safety-related certifications, such as such as ATmosphere EXplosible (ATEX), Restriction of Hazardous Substances (RoHS), Registration, Evaluation, Authorisation and Restriction of Chemicals (REACH) and waste electrical and electronic equipment (WEEE).

“Going directly to certification or carrier organizations can result in it taking up to six months for IoT devices to gain certifications,” said Yoon Seungryoul, North American Certification Director, Quectel Wireless Solutions. “For many IoT use cases a six-month delay to launch is unacceptable and could make or break a proposition in markets where being first-to-launch is a critical differentiator. This is why Quectel, with our Quectel Certification Services, is bringing to customers our existing knowledge of certification and testing processes and our relationships with authorities, certification bodies, regulators, and carriers to provide our customers with the industry’s fastest and most cost-effective go-to-market offering.”

To further help customers, Quectel Certification Services offers a pre-scan service in its own labs so certification compliance can be assessed before applying to certification authorities, thereby saving time on non-compliant certification applications. A further benefit for customers that utilize both Quectel modules and antennas in their design, is that device testing is included for free. Quectel also offers technical support facilities and debugging solutions to address common, and not so common, certification issues.

Quectel’s capabilities include project management, administration, lab and carrier communications and management, checking and managing test scope, providing the necessary on-site support, and providing testing and debugging. In addition, Quectel will fix issues as they arise and negotiate waivers where appropriate.

“We’re proud to have launched Quectel Certification Services and we’re ready to provide full, global certification consultation and service to integrated device customers that have products that are based on Quectel modules,” added Seungryoul. “Quectel Certification Services have been gaining certifications for Quectel’s own modules and customers’ devices for many years, so we’re delighted to be bringing this expertise to customers and helping them accelerate time-to-market and build a smarter world.”

About Quectel

Quectel’s passion for a smarter world drives us to accelerate IoT innovation. A highly customer-centric organization, we are a global IoT solutions provider backed by outstanding support and services. Our growing global team of over 4,000 professionals sets the pace for innovation in cellular, GNSS, Wi-Fi and Bluetooth modules, antennas and IoT connectivity.

With regional offices and support across the globe, our international leadership is devoted to advancing IoT and helping build a smarter world.

For more information: www.quectel.com, LinkedIn, Facebook, and Twitter.

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

Media contact:
Phil Rawcliffe, Head of Communications
phil.rawcliffe@quectel.com

About Business Wire

Business Wire
Business Wire
24 Martin Lane
EC4R 0DR London

+44 20 7626 1982http://www.businesswire.co.uk

(c) 2018 Business Wire, Inc., All rights reserved.

Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

HCLTech Reports FY24 Revenue of $13.3 Billion, up 5.4% YoY26.4.2024 22:06:00 CEST | Press release

HCLTech, a leading global technology company, today reported financial results for the fourth quarter and the full year ended March 31, 2024. The company reported full year revenue of $13.3 billion, up 5.4% YoY. Digital Services revenue grew by 5.3% (CC) and now contributes to 37.3% of IT Services revenue. HCLSoftware’s Annual Recurring Revenue came in at $1.02 billion. During FY24, the company won 73 large deals – 36 in Services and 37 in Software - that translated into TCV (new deal wins) of $9.76 billion, up 10% YoY. For the quarter, revenue came in at $3.43 billion, up 6% YoY. HCLTech won 21 large deals – 13 in Services and eight in Software, with a TCV of $2.29 billion during the quarter. In terms of geographies, Americas was the fastest growing region with 6.8% YoY (CC) growth followed by Europe, which grew by 5.5% YoY (CC). Industry vertical growth was led by Financial Services and Telecommunications, Media, Publishing & Entertainment. While Financial Services grew at 12.1% YoY

Kinaxis Positioned Highest on Ability to Execute in the Gartner® Magic Quadrant™ for Supply Chain Planning Solutions26.4.2024 18:03:00 CEST | Press release

Kinaxis® Inc. (TSX:KXS), a global leader in end-to-end supply chain orchestration, today announced it has been named a Leader in the 2024 Gartner® Magic Quadrant™ for Supply Chain Planning Solutions. Of the 20 vendors evaluated, Gartner positioned Kinaxis highest on Ability to Execute, marking the company’s 10th consecutive Leaders Quadrant within the report, a complimentary copy of which can be downloaded here. Kinaxis attributes its position to its patented concurrency approach and a proven track record of delivering innovative solutions against the foundation of its leading vision through the use of advanced technology such as AI, ML, and an intuitive user experience. Bolstered by a rich ecosystem of third-party implementation partners, Kinaxis continues to demonstrate that regardless of a customer’s industry, size, or maturity level, the company can be counted on to seamlessly orchestrate supply chain networks end-to-end from strategic planning to last-mile delivery. The recognitio

Vertex Announces European Commission Approval for KALYDECO ® to Treat Infants With Cystic Fibrosis Ages 1 Month and Older26.4.2024 17:43:00 CEST | Press release

Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Commission has granted approval for the label expansion of KALYDECO® (ivacaftor) for the treatment of infants down to 1 month of age with cystic fibrosis (CF) who have one of the following mutations in the cystic fibrosis transmembrane conductance regulator (CFTR) gene: R117H, G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. “Today’s approval is an important milestone for the cystic fibrosis community. Treating CF early in life can potentially slow the progression of the disease, which is why it is so important to start treatment from a very young age,” said Carmen Bozic, M.D., Executive Vice President, Global Medicines Development and Medical Affairs, and Chief Medical Officer, Vertex. As a result of existing access agreements in Austria, Czech Republic, Denmark, Ireland, Norway, Sweden, and The Netherlands, eligible patients will have access to the expanded indication of KALYDECO® (ivacaftor)

Suzano 2023 annual report on Form 20-F26.4.2024 17:22:00 CEST | Press release

Suzano S.A. (B3: SUZB3 | NYSE: SUZ) informs that its 2023 Annual Report on Form 20-F was filed today with the U.S. Securities and Exchange Commission. Holders of the Company’s equity securities can receive hard copies of the Annual Report, including its audited financial statements, without charge by request directed to: ri@suzano.com.br. This document is also available on Suzano’s website (http://ir.suzano.com.br/). For further information, please contact our Investor Relations Department: Phone: (+55 11) 3503-9330 E-mail: ri@suzano.com.br View source version on businesswire.com: https://www.businesswire.com/news/home/20240426289818/en/Contact information Hawthorn Advisors suzano@hawthornadvisors.com

Takeda Receives Positive CHMP Opinion for Fruquintinib in Previously Treated Metastatic Colorectal Cancer26.4.2024 14:30:00 CEST | Press release

Takeda (TSE:4502/NYSE:TAK) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has recommended the approval of fruquintinib, a selective inhibitor of vascular endothelial growth factor receptors (VEGFR) -1, -2 and -3 for the treatment of adult patients with previously treated metastatic colorectal cancer (mCRC). The European Commission (EC) will consider the CHMP positive opinion when determining the potential marketing authorization for fruquintinib for mCRC throughout the European Union (EU), Norway, Liechtenstein and Iceland. If approved, fruquintinib will be the first and only selective inhibitor of all three VEGF receptors approved in the EU for previously treated mCRC.1,2 “People living with metastatic colorectal cancer in the European Union currently have limited treatment options, which can lead to poor outcomes. With this positive opinion for fruquintinib, we are one step closer to potentially offering patients a new

HiddenA line styled icon from Orion Icon Library.Eye